NASDAQ:LGND - Ligand Pharmaceuticals Stock Price, Forecast & News

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) posted its quarterly earnings data on Thursday, February, 6th. The biotechnology company reported $0.71 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.07. The biotechnology company had revenue of $27 million for the quarter, compared to analyst estimates of $25.30 million. Ligand Pharmaceuticals had a return on equity of 4.34% and a net margin of 523.19%. The business's revenue was down 54.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.70 earnings per share. View Ligand Pharmaceuticals' Earnings History.

Ligand Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Ligand Pharmaceuticals.

Ligand Pharmaceuticals issued an update on its FY20 earnings guidance on Thursday, February, 6th. The company provided earnings per share guidance of Approx $3.40 for the period, compared to the Thomson Reuters consensus estimate of $3.49. The company issued revenue guidance of Approx $121 million, compared to the consensus revenue estimate of $126.51 million.

5 brokerages have issued 12 month target prices for Ligand Pharmaceuticals' stock. Their forecasts range from $132.00 to $237.00. On average, they anticipate Ligand Pharmaceuticals' stock price to reach $164.80 in the next year. This suggests a possible upside of 63.6% from the stock's current price. View Analyst Price Targets for Ligand Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ligand Pharmaceuticals.

Media coverage about LGND stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ligand Pharmaceuticals earned a news impact score of -1.8 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Ligand Pharmaceuticals.

Some companies that are related to Ligand Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Illumina (ILMN), Netflix (NFLX), Gilead Sciences (GILD), AbbVie (ABBV), Intel (INTC) and salesforce.com (CRM).

Ligand Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (10.35%), William Blair Investment Management LLC (8.07%), Renaissance Technologies LLC (5.81%), Conestoga Capital Advisors LLC (3.53%), Thrivent Financial for Lutherans (3.01%) and Rice Hall James & Associates LLC (1.72%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba, Sunil Patel and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.

LGND stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Renaissance Technologies LLC, AJO LP, Victory Capital Management Inc., Victory Capital Management Inc., AQR Capital Management LLC, Sei Investments Co. and CIBC Private Wealth Group LLC. View Insider Buying and Selling for Ligand Pharmaceuticals.

LGND stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Thrivent Financial for Lutherans, William Blair Investment Management LLC, California Public Employees Retirement System, KBC Group NV, Eaton Vance Management, Tygh Capital Management Inc. and Credit Suisse AG. Company insiders that have bought Ligand Pharmaceuticals stock in the last two years include Jason Aryeh, John L Higgins and Sunil Patel. View Insider Buying and Selling for Ligand Pharmaceuticals.

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LGND stock can currently be purchased for approximately $100.73.

Ligand Pharmaceuticals has a market capitalization of $1.77 billion and generates $120.28 million in revenue each year. The biotechnology company earns $629.30 million in net income (profit) each year or $2.11 on an earnings per share basis. Ligand Pharmaceuticals employs 116 workers across the globe.View Additional Information About Ligand Pharmaceuticals.

The official website for Ligand Pharmaceuticals is http://www.ligand.com/.

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]